复方斑蝥胶囊治疗肝细胞癌的分子靶点与机制:网络药理学与生物信息学分析
本研究采用网络药理学与生物信息学分析,筛选复方斑蝥胶囊的活性成分、潜在靶点及肝细胞癌差异表达基因,构建成分-靶点与基因-通路网络,并通过细胞实验验证核心靶点。结果显示CCNB1与CDK1为核心基因靶点,CMC含药血清可抑制HepG2细胞活力、下调CCNB1和CDK1表达并诱导G2/M期细胞周期阻滞。
要点
- 复方斑蝥胶囊通过多成分、多靶点、多通路机制发挥抗肝细胞癌作用。
- CCNB1和CDK1可能是复方斑蝥胶囊治疗肝细胞癌的核心分子靶点。
- CMC含药血清可抑制HepG2细胞活力并诱导G2/M期细胞周期阻滞。
核心结论
- 复方斑蝥胶囊通过多成分、多靶点、多通路机制发挥治疗肝细胞癌的作用,其中CCNB1和CDK1可能是核心分子靶点。
研究设计与样本
- 研究首先从公开数据库检索CMC的生物活性成分与潜在靶点以及HCC相关靶点,利用生物信息学分析确定重叠基因,构建成分-靶点与基因-通路网络,最后通过细胞实验检验CMC含药血清对HCC的影响并验证核心分子靶点。
主要发现
- 共筛选出CMC的151个生物活性成分和255个潜在靶点,鉴定出HCC的982个差异表达基因,最终选定34个重叠基因。
- 显著富集到20条通路和429个GO条目,蛋白质-蛋白质相互作用及基因-通路网络提示CCNB1和CDK1为CMC治疗HCC的核心基因靶点。
- 体外研究表明CMC含药血清显著抑制HepG2细胞活力,并下调CCNB1和CDK1表达、诱导G2/M期细胞周期阻滞。
临床怎么用
- 本研究为复方斑蝥胶囊治疗肝细胞癌提供了分子靶点与通路层面的机制解释,提示CCNB1和CDK1可作为潜在疗效相关标志物或进一步研究靶点。
局限性
- 研究结论主要基于网络药理学预测和体外细胞实验验证,尚需体内实验及临床研究进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Traditional Chinese herbal formulas have been proven to exert an inhibitory effect on tumor. Compound mylabris capsules (CMC) has been used for treating cancer, especially hepatocellular carcinoma (HCC), for years in China. However, its therapeutic mechanisms on HCC remain unclear. AIM OF THE STUDY: This research aimed to elucidate the molecular targets and mechanisms of CMC for treating HCC. MATERIALS AND METHODS: First, the bioactive ingredients and potential targets of CMC, as well as HCC-related targets were retrieved from publicly available databases. Next, the overlapped genes between potential targets of CMC and HCC-related targets were determined using bioinformatics analysis. Then, networks of ingredient-target and gene-pathway were constructed. Finally, cell experiments were carried out to examine the effects of CMC-medicated serum on HCC and validate the core molecular targets. RESULTS: In total, 151 bioactive ingredients and 255 potential targets of CMC were selected, 982 differentially expressed genes of HCC were identified. Among them, 34 overlapped genes were finally selected. In addition, 20 pathways and 429 GO terms were significantly enriched. Protein-protein interaction and gene-pathway networks indicated that Cyclin B1(CCNB1) and Cyclin Dependent Kinase 1(CDK1) were the core gene targets for the treatment of CMC on HCC. Moreover, in vitro studies showed that CMC-medicated serum significantly inhibited the viability of HepG2 cells. Furthermore, CMC downregulated CCNB1 and CDK1 expressions and induced G2/M phase cell cycle arrest. CONCLUSIONS: CMC plays a therapeutic role in HCC via multi-component, -target and -pathway mechanisms, in which CCNB1 and CDK1 may be the core molecular targets. This study indicates that the integration of network pharmacology and bioinformatics analysis, followed by experimental validation, can serves as an effective tool for studying the therapeutic mechanisms of traditional Chinese medicine.
引用
- Wei J, Ma L, Liu W, et al. Identification of the molecular targets and mechanisms of compound mylabris capsules for hepatocellular carcinoma treatment through network pharmacology and bioinformatics analysis. J Ethnopharmacol. 2021. PMID: 33932512. doi:10.1016/j.jep.2021.114174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。